1. Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients
    Yu Sawada et al, 2016, OncoImmunology CrossRef
  2. Potentiality of immunotherapy against hepatocellular carcinoma
    Nobuhiro Tsuchiya, 2015, WJG CrossRef
  3. Current status and perspectives of immune-based therapies for hepatocellular carcinoma
    Maridi Aerts, 2016, WJG CrossRef
  4. Circulating biomarkers of hepatocellular carcinoma response after locoregional treatments: New insights
    Maria Tampaki, 2015, WJH CrossRef
  5. Prospects for immunotherapy as a novel therapeutic strategy against hepatocellular carcinoma
    Yu Akazawa et al, 2019, WJMA CrossRef
  6. Immunotherapy for hepatocellular carcinoma: Current and future
    Michael P Johnston et al, 2019, WJG CrossRef
  7. Immune Checkpoint Inhibitors as Monotherapy or Within a Combinatorial Strategy in Advanced Hepatocellular Carcinoma
    Michela Guardascione et al, 2020, IJMS CrossRef
  8. Translational Considerations to Improve Response and Overcome Therapy Resistance in Immunotherapy for Hepatocellular Carcinoma
    Sophia Heinrich et al, 2020, Cancers CrossRef
  9. Immunmodulatory Treatment Strategies of Hepatocellular Carcinoma: From Checkpoint Inhibitors Now to an Integrated Approach in the Future
    Matthias Ocker et al, 2021, Cancers CrossRef
  10. Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors and Applicability of First-Line Atezolizumab/Bevacizumab in a Real-Life Setting
    Maria Corina Plaz Torres et al, 2021, JCM CrossRef
  11. Immune Responses Following Locoregional Treatment for Hepatocellular Carcinoma: Possible Roles of Adjuvant Immunotherapy
    Ji-Won Han et al, 2021, Pharmaceutics CrossRef
  12. Immunological Markers, Prognostic Factors and Challenges Following Curative Treatments for Hepatocellular Carcinoma
    Soon Kyu Lee et al, 2021, IJMS CrossRef
  13. Thermal ablation and immunotherapy for hepatocellular carcinoma: Recent advances and future directions
    Xiao-Wan Bo et al, 2021, WJGO CrossRef
  14. Identification of Gene-Set Signature in Early-Stage Hepatocellular Carcinoma and Relevant Immune Characteristics
    Qijie Zhao et al, 2021, Front. Oncol. CrossRef
  15. PD-1 expression in hepatocellular carcinoma predicts liver-directed therapy response and bridge-to-transplant survival
    Kelley G. Núñez et al, 2021, Cancer Immunol Immunother CrossRef
  16. Combination of Ablation and Immunotherapy for Hepatocellular Carcinoma: Where We Are and Where to Go
    Kunpeng Wang et al, 2021, Front. Immunol. CrossRef
  17. Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: Monotherapies and Combined Therapies
    Tao Ouyang et al, 2022, Front. Oncol. CrossRef
  18. Distinct Gene Expression Profiles in Viable Hepatocellular Carcinoma Treated With Liver-Directed Therapy
    Kelley G. Núñez et al, 2022, Front. Oncol. CrossRef
  19. Impact and Novel Perspective of Immune Checkpoint Inhibitors in Patients with Early and Intermediate Stage HCC
    Luca Marzi et al, 2022, Cancers CrossRef
  20. Microwave ablation combined with apatinib and camrelizumab in patients with advanced hepatocellular carcinoma: A single-arm, preliminary study
    Xin Li et al, 2022, Front. Immunol. CrossRef
  21. In-situ tumor vaccination by percutaneous ablative therapy and its synergy with immunotherapeutics: An update on combination therapy
    Nicole J. Kim et al, 2023, Front. Immunol. CrossRef
  22. A Trinity Nano-Vaccine System with Spatiotemporal Immune Effect for the Adjuvant Cancer Therapy after Radiofrequency Ablation
    Minghui Li et al, 2023, ACS Nano CrossRef
  23. Achievement of Complete Response and Drug-Free Status by Atezolizumab plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-Stage Hepatocellular Carcinoma: A Multicenter Proof-Of-Concept Study
    Masatoshi Kudo et al, 2023, Liver Cancer CrossRef
  24. Radiofrequency ablation plays double role in immunosuppression and activation of PBMCs in recurrent hepatocellular carcinoma
    Yang Zhao et al, 2024, Front. Immunol. CrossRef